The progressive Role of Dyslipidemia and Inflammation in Type 2 Diabetes in Iraqi Patients

Type II diabetes is a complex metabolic disorder that raises the risk of dyslipidemia and obesity. Inflammation is the primary factor in the pathogenesis of this disease and coincides with metabolic dyslipidemia. This work aims to predict the role of dyslipidemia and inflammatory markers in development type II DM by evaluating the levels of lipid profile, TNF-R2, systemic immune inflammatory index (SII) and related biochemical factors in patients with type 2 diabetes. Thirty samples were obtained from diabetic patients and 30 samples from non-diabetic individuals as a control. D10 apparatus (BIO-RAD, USA) used to measure hemoglobin A1c HbA1c, Enzymatic and colorimetric method used to measure biochemical parameter, ELISA technique used to estimate the TNF-R2 levels, and Complete Blood Count determine to calculate SII by the formula (neutrophil *platelet / lymphocyte count) . The results showed significant increase in most of lipid profile levels in patients than control except HDL has the verse results. Also, the results showed that HbA1C was significantly increased in patient compared to healthy group. Furthermore, TNF-R2 and SII appeared higher significant values in patients than control. Furthermore, the results indicated positive correlation between HbA1C and lipid profile (TC, TGs, VLDL and LDL), TNF-R2, SII, and BMI. It can be concluded that dyslipidemia and both TNF-R2 and SII inflammatory parameters have a cardinal role in the development of T2DM and can be served as early diagnostic factors to detect disease progression.